https://scholars.lib.ntu.edu.tw/handle/123456789/578172
標題: | Rational combination with an immunotherapy backbone in genitourinary cancers | 作者: | JHE-CYUAN GUO CHIA-CHI LIN |
公開日期: | 2020 | 出版社: | Wolters Kluwer Medknow Publications | 卷: | 31 | 期: | 1 | 起(迄)頁: | 4-7 | 來源出版物: | Urological Science | 摘要: | Immunotherapy, especially immune checkpoint blockade treatment, has changed the landscape of anticancer therapy. In genitourinary (GU) cancer, the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) blockade alone has resulted in improved outcomes compared with conventional therapies, such as chemotherapy and targeted therapy in advanced urothelial carcinoma and renal cell carcinoma (RCC), respectively. To improve the efficacy of the PD-1/PD-L1 blockade, a combination of this blockade with other therapeutic modalities has been explored in the earnest. In a recent study, ipilimumab, an anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody, combined with nivolumab, an anti-PD-1 monoclonal antibody as the first-line therapy, has demonstrated superior efficacy to sunitinib in advanced RCC patients with International Metastatic RCC Database Consortium intermediate and poor risk. This mini-review article focuses on the rational combination with the PD-1/PD-L1 blockade in GU cancers. ? 2020 Iranian Journal of Nursing and Midwifery Research - Published by Wolters Kluwer -Medknow. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080950126&doi=10.4103%2fUROS.UROS_11_19&partnerID=40&md5=a9ca64d4c452f371af4020d00eeae50d https://scholars.lib.ntu.edu.tw/handle/123456789/578172 |
ISSN: | 1879-5226 | DOI: | 10.4103/UROS.UROS_11_19 | SDG/關鍵字: | ipilimumab; nivolumab; sunitinib; cancer combination chemotherapy; cancer immunotherapy; drug efficacy; human; priority journal; renal cell carcinoma; Review; transitional cell carcinoma; urogenital tract cancer |
顯示於: | 醫學院附設癌醫中心醫院(臺大癌醫) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。